Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 536 (LINC00536) is a long non-coding RNA classified as a lincRNA, meaning it is a transcript greater than 200 nucleotides that does not overlap protein-coding genes and is not translated into protein. LINC00536 has been reported to act as an oncogene in breast cancer, promoting cell proliferation, migration, and invasion. It is thought to influence cancer cell behavior and may serve as a potential biomarker for disease progression. LINC00536 does not encode a protein or function as a traditional druggable target such as an enzyme, receptor, or transporter; instead, it likely exerts regulatory roles at the transcriptional or epigenetic level as is common for lncRNAs. There are no known direct drug interactions or described mechanisms of pharmacological inhibition or activation for LINC00536.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 536 (LINC00536).